OPTN Quote, Financials, Valuation and Earnings

Alnylam Pharmaceuticals has a net margin of -121.1% compared to OptiNose's net margin of -9.67%. OptiNose's return on equity of -- beat Alnylam Pharmaceuticals's return on equity of --.

OptiNose has a consensus price target of $21.00, signalling upside risk potential of 118.75%. On the other hand Alnylam Pharmaceuticals has an analysts' consensus of $320.62 which suggests that it could grow by 10.57%. Given that OptiNose has higher upside potential than Alnylam Pharmaceuticals, analysts believe OptiNose is more attractive than Alnylam Pharmaceuticals.

OptiNose has a beta of -0.879, which suggesting that the stock is 187.86% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals has a beta of 0.169, suggesting its less volatile than the S&P 500 by 83.104%.

OptiNose has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OptiNose pays -- of its earnings as a dividend. Alnylam Pharmaceuticals pays out -- of its earnings as a dividend.

OptiNose quarterly revenues are $18.5M, which are smaller than Alnylam Pharmaceuticals quarterly revenues of $594.2M. OptiNose's net income of -$22.4M is higher than Alnylam Pharmaceuticals's net income of -$57.5M. Notably, OptiNose's price-to-earnings ratio is -- while Alnylam Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OptiNose is 1.32x versus 15.87x for Alnylam Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Aptevo Therapeutics has a net margin of -121.1% compared to OptiNose's net margin of --. OptiNose's return on equity of -- beat Aptevo Therapeutics's return on equity of --.

OptiNose has a consensus price target of $21.00, signalling upside risk potential of 118.75%. On the other hand Aptevo Therapeutics has an analysts' consensus of $21.00 which suggests that it could grow by 7525.27%. Given that Aptevo Therapeutics has higher upside potential than OptiNose, analysts believe Aptevo Therapeutics is more attractive than OptiNose.

OptiNose has a beta of -0.879, which suggesting that the stock is 187.86% less volatile than S&P 500. In comparison Aptevo Therapeutics has a beta of 6.064, suggesting its more volatile than the S&P 500 by 506.406%.

OptiNose has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aptevo Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OptiNose pays -- of its earnings as a dividend. Aptevo Therapeutics pays out -- of its earnings as a dividend.

OptiNose quarterly revenues are $18.5M, which are larger than Aptevo Therapeutics quarterly revenues of --. OptiNose's net income of -$22.4M is lower than Aptevo Therapeutics's net income of -$6.4M. Notably, OptiNose's price-to-earnings ratio is -- while Aptevo Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OptiNose is 1.32x versus 0.01x for Aptevo Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Ionis Pharmaceuticals has a net margin of -121.1% compared to OptiNose's net margin of -111.65%. OptiNose's return on equity of -- beat Ionis Pharmaceuticals's return on equity of -100.15%.

OptiNose has a consensus price target of $21.00, signalling upside risk potential of 118.75%. On the other hand Ionis Pharmaceuticals has an analysts' consensus of $57.54 which suggests that it could grow by 74.47%. Given that OptiNose has higher upside potential than Ionis Pharmaceuticals, analysts believe OptiNose is more attractive than Ionis Pharmaceuticals.

OptiNose has a beta of -0.879, which suggesting that the stock is 187.86% less volatile than S&P 500. In comparison Ionis Pharmaceuticals has a beta of 0.151, suggesting its less volatile than the S&P 500 by 84.865%.

OptiNose has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OptiNose pays -- of its earnings as a dividend. Ionis Pharmaceuticals pays out -- of its earnings as a dividend.

OptiNose quarterly revenues are $18.5M, which are smaller than Ionis Pharmaceuticals quarterly revenues of $131.6M. OptiNose's net income of -$22.4M is higher than Ionis Pharmaceuticals's net income of -$146.9M. Notably, OptiNose's price-to-earnings ratio is -- while Ionis Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OptiNose is 1.32x versus 7.03x for Ionis Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Cassava Sciences has a net margin of -121.1% compared to OptiNose's net margin of --. OptiNose's return on equity of -- beat Cassava Sciences's return on equity of --.

OptiNose has a consensus price target of $21.00, signalling upside risk potential of 118.75%. On the other hand Cassava Sciences has an analysts' consensus of $2.00 which suggests that it could fall by -5.21%. Given that OptiNose has higher upside potential than Cassava Sciences, analysts believe OptiNose is more attractive than Cassava Sciences.

OptiNose has a beta of -0.879, which suggesting that the stock is 187.86% less volatile than S&P 500. In comparison Cassava Sciences has a beta of -2.309, suggesting its less volatile than the S&P 500 by 330.898%.

OptiNose has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cassava Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OptiNose pays -- of its earnings as a dividend. Cassava Sciences pays out -- of its earnings as a dividend.

OptiNose quarterly revenues are $18.5M, which are larger than Cassava Sciences quarterly revenues of --. OptiNose's net income of -$22.4M is higher than Cassava Sciences's net income of -$23.4M. Notably, OptiNose's price-to-earnings ratio is -- while Cassava Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OptiNose is 1.32x versus 2.44x for Cassava Sciences. Usually stocks with elevated PS ratios are considered overvalued.